​

Crescent Biopharma (CBIO) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CBIO Stock Forecast

Crescent Biopharma (CBIO) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $33.00, with a high of $35.00 and a low of $29.00. This represents a 70.10% increase from the last price of $19.40.

CBIO Stock Rating

Crescent Biopharma stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (69.23%), 4 Hold (30.77%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 4 9 Strong Sell Sell Hold Buy Strong Buy

CBIO Price Target Upside V Benchmarks

TypeNameUpside
StockCrescent Biopharma70.10%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-35
Avg Price Target-$33.00$31.40
Last Closing Price$19.40$19.40$19.40
Upside/Downside-70.10%61.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2618---9
Mar, 2618---9
Feb, 2618---9
Jan, 26-7---7
Dec, 25-7---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Stephen WilleyStifel Nicolaus$29.00$12.35134.82%49.48%
Jan 28, 2026Piper Sandler$35.00$11.27210.56%80.41%
Jan 21, 2026Brad CaninoGuggenheim$35.00$13.98150.36%80.41%
Dec 04, 2025Stephen WilleyStifel Nicolaus$32.00$12.99146.34%64.95%
Aug 25, 2025Jefferies$26.00$14.7076.87%34.02%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 28, 2026Piper SandlerOverweightinitialise
Jan 21, 2026GuggenheimBuyinitialise
Aug 25, 2025JefferiesBuyinitialise
Jul 14, 2025WedbushOutperforminitialise

Financial Forecast

EPS Forecast

$-15K $-12K $-9K $-6K $-3K $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-1.23$-0.89$-0.58$-0.59$-12.82K--
Avg Forecast$-2.65$-0.98$-0.16$-0.03$-7.88$-4.94$-2.99
High Forecast$-2.65$-0.98$-0.16$-0.03$-6.00$-3.31$-1.98
Low Forecast$-2.65$-0.98$-0.16$-0.03$-10.47$-8.00$-3.58
Surprise %-53.58%-9.18%262.50%1866.67%162565.10%--

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$1.16M$75.00K$10.00K----
Avg Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
High Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
Low Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
Surprise %53.02%-90.55%-99.37%----

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-63.43M$-46.69M$-36.90M$-71.47M$-149.94M--
Avg Forecast$-83.60M$-30.91M$-5.93M$-30.69K$-8.42M$-5.78M$-2.84M
High Forecast$-83.60M$-30.91M$-5.05M$-30.69K$-6.14M$-3.39M$-2.03M
Low Forecast$-83.60M$-30.91M$-5.05M$-30.69K$-10.71M$-8.18M$-3.66M
Surprise %-24.13%51.02%522.46%232785.82%1679.96%--

CBIO Forecast FAQ

Is Crescent Biopharma stock a buy?

Crescent Biopharma stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Crescent Biopharma is a favorable investment for most analysts.

What is Crescent Biopharma's price target?

Crescent Biopharma's price target, set by 13 Wall Street analysts, averages $33 over the next 12 months. The price target range spans from $29 at the low end to $35 at the high end, suggesting a potential 70.10% change from the previous closing price of $19.4.

How does Crescent Biopharma stock forecast compare to its benchmarks?

Crescent Biopharma's stock forecast shows a 70.10% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Crescent Biopharma over the past three months?

  • April 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Crescent Biopharma’s EPS forecast?

Crescent Biopharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.94, marking a -99.96% decrease from the reported $-12.818K in 2025. Estimates for the following years are.

What is Crescent Biopharma’s revenue forecast?

Crescent Biopharma's average annual revenue forecast for its fiscal year ending in December 2026 is $39.95M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is Crescent Biopharma’s net income forecast?

Crescent Biopharma's net income forecast for the fiscal year ending in December 2026 stands at $-5.785M, representing a -96.14% decrease from the reported $-150M in 2025. Projections indicate .